Examining ‘Big Pharma Invented Disease Labels’ Claims: A Timeline of Key Dates, Documents, and Turning Points

This timeline examines the claim that “Big Pharma invented disease labels” by tracing key dates, documents, and turning points. We treat the phrase “Big Pharma invented disease labels” as an allegation and focus on documented events — regulatory approvals, peer-reviewed trials, influential publications, and evidence about industry ties — that supporters and critics cite when discussing whether pharmaceutical companies created or expanded diagnostic categories.

Timeline: key dates and turning points

1672 — Early descriptions of restlessness and limb sensations. Sir Thomas Willis and later clinicians recorded symptoms similar to what is now called restless legs syndrome, showing that some diagnostic concepts have long clinical histories predating modern pharmaceutical marketing.
1945–1950s — Ekbom and systematic description of restless legs. Karl-Axel Ekbom published a detailed account that popularized the name and clinical picture later called Ekbom or restless legs syndrome. This is an example where a named clinical syndrome emerged from academic clinical observation long before recent drug marketing campaigns.
1987–1994 — Psychiatric diagnostic development and formal proposals for menstrual‑cycle‑related disorders. Diagnostic categories for cyclical mood disorders (precursors to what later became PMDD) appeared in psychiatric manuals and appendices as proposed diagnoses needing study; deliberations about inclusion show diagnostic categories evolve within clinical and research communities as evidence accumulates.
1995 — Randomized clinical trial: fluoxetine for late‑luteal‑phase dysphoria (PMDD precursor). A multi‑center randomized controlled trial published in the New England Journal of Medicine found fluoxetine superior to placebo for symptoms of late‑luteal‑phase dysphoria, providing clinical-trial evidence that influenced subsequent diagnostic and regulatory discussions.
2000 — FDA approval/marketing shift: Eli Lilly’s Sarafem labeled for premenstrual dysphoric disorder; public education campaigns followed. Following clinical trial evidence and regulatory discussion, Eli Lilly marketed fluoxetine under the trade name Sarafem for PMDD and supported public education efforts to differentiate PMDD from depression — a move critics cite as an example of commercial rebranding tied to a drug’s patent lifecycle.
2002 — Academic and media scrutiny: BMJ’s “Selling Sickness” and disease‑mongering critique. Ray Moynihan and colleagues published influential critiques (and later a book, Selling Sickness) that coined and popularized the term “disease mongering,” arguing pharmaceutical marketing can broaden disease definitions and create demand. These critiques marked a turning point in public debate about whether industry activities expand diagnostic boundaries.
2003–2006 — Organized scrutiny and conference activity on disease mongering. Academics, journalists, and public‑health advocates organized conferences and published collections (including PLOS Medicine material) to examine how marketing, clinical practice, and media attention interact when a condition becomes widely recognized — framing the issue as complex and multi‑sourced rather than attributable exclusively to industry.
2005 — FDA approves ropinirole for restless legs syndrome; subsequent advertising and awareness campaigns are criticized by some as “disease mongering.” Requip’s approval and the aggressive marketing around RLS (including surveys and awareness statements) are cited in case studies that explore how industry promotion can raise recognition and treatment rates; independent researchers have documented both benefits and concerns (including overdiagnosis and shifting prescribing patterns).
Mid‑2000s onward — Studies document ties between guideline/manual authors and industry. Investigations found substantial financial relationships between DSM (psychiatric diagnostic manual) panel members and pharmaceutical companies around the DSM‑IV and later revisions; these disclosures fueled debate about whether industry ties might bias diagnostic criteria. Multiple analyses and commentaries documented the prevalence of such ties, while other commentators cautioned against assuming direct causality.
2014 — FDA safety communications and advisory activity regarding testosterone labeling, reflecting scrutiny of how expanded use of a treatment (“Low T”) intersected with marketing and safety concerns. The FDA issued a Drug Safety Communication in 2014 warning about testosterone product use for age‑related low testosterone and requested labeling changes; the action followed public and regulatory debate about rapidly rising prescriptions beyond established indications. Critics framed the episode as an example of market expansion; regulators responded by highlighting safety and approved‑use concerns.
2024 — Regulatory follow‑up: Eli Lilly requested withdrawal of Sarafem (PMDD indication) marketing authorization, reflecting changes in product marketing and labeling over time. In 2024 the FDA published a notice indicating Eli Lilly was withdrawing approval for Sarafem (the PMDD‑indicated formulation of fluoxetine) because the product is no longer marketed — an example of how product availability and indications can shift decades after initial approval. This administrative step does not by itself resolve debates about historical origins or influence on diagnostic categories.

Where the timeline gets disputed

Supporters of the claim “Big Pharma invented disease labels” typically point to coordinated marketing campaigns, re‑branding of existing drugs, sponsorship of clinical trials, and financial links between industry and guideline or manual authors as evidence that pharmaceutical companies drove the creation or expansion of diagnostic categories. Critics of that interpretation argue the historical record shows many diagnostic categories predate modern marketing, that peer‑reviewed trials and regulatory approvals often base decisions on clinical data, and that industry ties are not proof of causal influence on diagnostic science. The literature documenting both practices and ties is real; what is disputed is the causal interpretation — whether those ties caused the invention of labels or whether they primarily affected awareness, treatment patterns, and market share.

Key contested points include:

Timing and causation: Did industry marketing create entirely new diagnostic categories, or did it primarily raise awareness and increase diagnosis rates for conditions already described in the clinical literature? Evidence shows both long clinical histories for some conditions (e.g., RLS) and more recent clinical trials for other categories (e.g., PMDD), making simple causal claims difficult to prove.
Role of clinical evidence vs marketing: Some category expansions followed randomized trials and formal regulatory review; others coincided with heavy marketing. Distinguishing whether trials were initiated primarily for scientific reasons or commercial reasons is often contested and can vary case by case.
Interpretation of financial ties: Multiple studies documented extensive financial relationships between diagnostic‑panel members and industry; those ties raise conflict‑of‑interest concerns but do not automatically prove that diagnostic criteria were invented for commercial gain — researchers disagree about the magnitude and practical effect of such ties.

Evidence score (and what it means)

Evidence score: 42/100

Documented: There is clear documentation of industry marketing campaigns, regulatory approvals tied to clinical trials, and published critiques (BMJ, PLOS Medicine) describing “disease mongering.”
Documented: Multiple randomized controlled trials exist showing clinical benefit for some labeled conditions (for example, fluoxetine trials for PMDD).
Documented: Investigations and peer‑reviewed analyses show substantial financial ties between some guideline/manual authors and the pharmaceutical industry, especially in psychiatry.
Gaps: Causal linkage — proving that companies invented labels rather than capitalized on or accelerated existing research/clinical descriptions — is weak or case‑specific; direct documentary evidence that a company wrote a diagnostic definition and compelled its adoption is rare.
Conflicts: Where evidence exists, interpretations conflict — some sources emphasize commercial motive and tangible marketing strategies, others emphasize legitimate scientific and regulatory processes.

Evidence score is not probability:
The score reflects how strong the documentation is, not how likely the claim is to be true.

FAQ

Q: What do people mean when they say “Big Pharma invented disease labels”?

A: The phrase is shorthand for a set of claims that pharmaceutical companies (1) manufactured or exaggerated diagnostic categories to create markets for drugs, or (2) accelerated recognition of conditions through marketing and sponsored research. Those are distinct claims — one alleges invention of labels, the other alleges amplification — and the evidence base supports amplification in many documented episodes while strict invention is far harder to demonstrate.

Q: Is there documented evidence that drug companies funded trials leading to new diagnostic labels?

A: Yes. Industry‑funded clinical trials exist (for example, fluoxetine studies for late‑luteal‑phase dysphoria that influenced PMDD discussions), and companies have sponsored trials and public education campaigns that accompanied regulatory submissions. Documentation of funding and trials is available in scientific literature and regulatory filings; how to interpret those ties is debated.

Q: Do diagnostic manuals like the DSM have conflicts of interest with industry?

A: Multiple peer‑reviewed analyses have documented financial relationships between DSM panel contributors and pharmaceutical firms (e.g., analyses of DSM‑IV era panelists). Those findings are documented and have driven calls for stronger conflict‑of‑interest policies; however, documentation of ties does not, by itself, prove that specific diagnostic changes were intentionally made to serve commercial interests.

Q: Which real‑world examples are frequently cited in these debates?

A: Frequently cited case studies include premenstrual dysphoric disorder and the Sarafem marketing story, the growth in testosterone (“Low T”) prescribing and related safety reviews, and promotion around restless legs syndrome linked to drugs like ropinirole. Each example contains documented facts (clinical trials, regulatory approvals, marketing campaigns) but also contested interpretations about causation and intent.

Q: How should a reader use this timeline when evaluating the claim that Big Pharma invented disease labels?

A: Use the timeline to separate (1) verifiable events — trials, approvals, documented industry payments, public communications — from (2) contested inferences about motive or causation. When evaluating specific assertions, look for primary documents (trial papers, FDA records, disclosures) and note whether independent researchers or multiple lines of evidence corroborate the claimed causal chain. Where evidence conflicts or is absent, the claim should be treated as unproven.

“This article is for informational and analytical purposes and does not constitute legal, medical, investment, or purchasing advice.”

What we still don’t know

Across the examples documented in the literature, the central unresolved questions are causal and case‑specific: did industry action create a diagnostic category that would not otherwise have existed, or did companies primarily accelerate recognition and treatment of conditions that had independent clinical evidence? For several high‑profile examples there is documentation for both industry involvement and independent clinical research; disentangling the relative contributions of each requires access to internal strategy documents, contemporaneous communications, and records of decision‑making inside guideline or regulatory committees — records that are not uniformly public. Where internal records are unavailable or contradictory, reasonable people and researchers reach different conclusions.